Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa
Open accessAbstract
Retinitis pigmentosa is a form of retinal degeneration usually caused by genetic mutations affecting key functional proteins. We have previously demonstrated efficacy in a mouse model of RLBP1 deficiency with a self-complementary AAV8 vector carrying the gene for human RLBP1 under control of a short RLBP1 promoter (CPK850). 1 In this article, we describe the nonclinical safety profile of this construct as well as updated efficacy data in the intended clinical formulation. In Rlbp1 −/− mice dosed at a range of CPK850 levels, a minimum efficacious dose of 3 × 10 7 vg in a volume of 1 μL was observed. For safety assessment in these and Rlbp1 +/+ mice, optical coherence tomography (OCT) and histopathological analysis indicated retinal thinning that appeared to be dose-dependent for both Rlbp1 genotypes, with no qualitative difference noted between Rlbp1 +/+ and Rlbp1 −/− mice. In a non-human primate study, RLBP1 mRNA expression was detected and dose dependent intraocular inflammation and retinal thinning were observed. Inflammation resolved slowly over time and did not appear to be exacerbated in the presence of anti-AAV8 antibodies. Biodistribution was evaluated in rats and satellite animals in the non-human primate study. The vector was largely detected in ocular tissues and low levels in the optic nerve, superior colliculus, and lateral geniculate nucleus, with limited distribution outside of these tissues. These data suggest that an initial subretinal dose of ∼3 × 10 7 vg/μL CPK850 can safely be used in clinical trials.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Subretinal injections for viral gene therapy may trigger host immune responses.
“Subretinal injections for viral gene therapy may trigger host immune responses [258,288,289,290,291]”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [291]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · see citing works
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · see citing works
Genes and mutations causing retinitis pigmentosa
Daiger, S. P., Sullivan, L. S., & Bowne, S. J. (2013) · Clinical Genetics · doi:10.1111/cge.12203 · Cited by 625 · see citing works
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461 · see citing works
Diseases Caused by Defects in the Visual Cycle: Retinoids as Potential Therapeutic Agents
Travis, G. H., Golczak, M., Moise, A. R., & Palczewski, K. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105225 · Cited by 419 · see citing works
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395 · see citing works
Mehalow, A. K. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg232 · Cited by 377 · see citing works
The Cone-specific visual cycle
Wang, J.-S., & Kefalov, V. J. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.001 · Cited by 335 · see citing works
Maw, M. A., Kennedy, B. N., Knight, A., Bridges, R., Roth, K. E., Mani, E. J., Mukkadan, J. K., Nancarrow, D. J., Crabb, J. W., & Denton, M. J. (1997) · Nature Genetics · doi:10.1038/ng1097-198 · Cited by 325 · see citing works
Cideciyan, A. V., Hauswirth, W. W., Aleman, T. S., Kaushal, S., Schwartz, S. B., Boye, S. L., Windsor, E. A. M., Conlon, T. J., Sumaroka, A., Pang, J.-J., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.086 · Cited by 312 · see citing works
Wenzel, A., Remé, C. E., Williams, T. P., Hafezi, F., & Grimm, C. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00053.2001 · Cited by 291 · see citing works
Bennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300389 · Cited by 267 · see citing works
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224 · see citing works
The relationship between opsin overexpression and photoreceptor degeneration.
Tan, E., Wang, Q., Quiambao, A. B., Xu, X., Qtaishat, N. M., Peachey, N. S., Lem, J., Fliesler, S. J., Pepperberg, D. R., Naash, M. I., et al. (2001) · PubMed · Cited by 161 · see citing works
An Alternative Pathway Mediates the Mouse and Human Cone Visual Cycle
Wang, J.-S., & Kefalov, V. J. (2009) · Current Biology · doi:10.1016/j.cub.2009.07.054 · Cited by 155 · see citing works
Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147 · see citing works
Jacobson, S. G., Boye, S. L., Alemán, T. S., Conlon, T. J., Zeiss, C. J., Román, A. J., Cideciyan, A. V., Schwartz, S., Komáromy, A. M., Doobrajh, M., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.845 · Cited by 145 · see citing works
Amado, D., Mingozzi, F., Hui, D., Bennicelli, J. L., Wei, Z., Chen, Y., Bote, E., Grant, R. L., Golden, J. A., Narfstrom, K., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000659 · Cited by 140 · see citing works
Eichers, E. R., Green, J. S., Stockton, D. W., Jackman, C. S., Whelan, J., McNamara, J. A., Johnson, G. J., Lupski, J. R., & Katsanis, N. (2002) · The American Journal of Human Genetics · doi:10.1086/339688 · Cited by 101 · see citing works
He, X., Lobsiger, J., & Stocker, A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907454106 · Cited by 73 · see citing works
Functional and Anatomic Consequences of Subretinal Dosing in the Cynomolgus Macaque
Nork, T. M. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.295 · Cited by 72 · see citing works
Golovleva, I., Bhattacharya, S. K., Wu, Z., Shaw, N., Yang, Y., Andrabi, K. I., West, K. A., Burstedt, M. S. I., Forsman, K., Holmgren, G., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207300200 · Cited by 71 · see citing works
Ye, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64 · see citing works
Binley, K., Widdowson, P. S., Kelleher, M., de Belin, J., Loader, J., Ferrige, G., Carlucci, M., Esapa, M., Chipchase, D., Angell-Manning, D., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.008 · Cited by 61 · see citing works
Evaluation of an optimized injection system for retinal gene therapy in human patients
Fischer, M. D., Hickey, D. G., Singh, M. S., & MacLaren, R. E. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.086 · Cited by 61 · see citing works
Stability and Safety of an AAV Vector for Treating RPGR-ORF15 X-Linked Retinitis Pigmentosa
Deng, W., Dyka, F. M., Dinculescu, A., Li, J., Zhu, P., Chiodo, V. A., Boye, S. L., Conlon, T. J., Erger, K. E., Cossette, T. L., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.035 · Cited by 55 · see citing works
AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout mice
Choi, V. W., Bigelow, C. E., McGee, T. L., Gujar, A. N., Li, H., Hanks, S. M., Vrouvlianis, J., Maker, M., Leehy, B., Zhang, Y., et al. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.22 · Cited by 35 · see citing works
Self-citationYe, G.-J., Budzynski, E., Sonnentag, P. J., Nork, T. M., Miller, P. E., McPherson, L. E., Hoeve, J. N. V., Smith, L. M., Arndt, T., Mandapati, S., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.163 · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242 · see citing works
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173 · see citing works
Han, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60 · see citing works
Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays
Gorovits, B., Fiscella, M., Havert, M., Koren, E., Long, B., Milton, M., & Purushothama, S. (2020) · The AAPS Journal · doi:10.1208/s12248-019-0403-1 · Cited by 57 · see citing works
Self-citationLima de Carvalho, J. R., Kim, H. J., Ueda, K., Zhao, J., Owji, A. P., Yang, T., Tsang, S. H., & Sparrow, J. R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012695 · Cited by 42 · see citing works
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44 · see citing works
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33 · see citing works
- Authors
- MacLachlan, T. K., Milton, M. N., Turner, O., Tukov, F., Choi, V. W., Penraat, J., Hanks, S. M., Vrouvlianis, J., Leehy, B., Li, H., Delmotte, M.-H., Michaut, L., Jaffee, B. D., & Bigelow, C. E.
- Affiliations
- Novartis (Switzerland) (CH)
- Corresponding author
- MacLachlan, Timothy K.
- ORCID
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 8
- Pages
- 105-120
- ISSN
- 2329-0501 (ISSN-L)
- PMC
- PMC5772508
- OpenAlex
- W2779107368
- Cited by
- 40
- References
- 28
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 6 · 2019: 3 · 2018: 3
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Therapy — Methods & Clinical Development (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- gene therapy, preclinical safety, retinal degeneration, non-human primate toxicity, intraocular inflammation, retinal thinning, vector biodistribution, subretinal delivery, dose-dependent efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
